INT174816

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.09
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 14
Total Number 16
Disease Relevance 11.26
Pain Relevance 3.63

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IL6R) extracellular region (IL6R) plasma membrane (IL6R)
enzyme binding (IL6R)
Anatomy Link Frequency
blood 1
cervix 1
IL6R (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 121 99.44 Very High Very High Very High
Inflammation 149 99.00 Very High Very High Very High
rheumatoid arthritis 442 94.24 High High
Arthritis 261 83.84 Quite High
Etanercept 14 81.80 Quite High
Angina 6 81.28 Quite High
Infliximab 8 81.20 Quite High
methotrexate 294 75.84 Quite High
anakinra 15 71.48 Quite High
Pain 13 70.24 Quite High
Disease Link Frequency Relevance Heat
Cancer 51 99.52 Very High Very High Very High
INFLAMMATION 162 99.00 Very High Very High Very High
Injury 2 98.60 Very High Very High Very High
Multiple Myeloma 1 98.08 Very High Very High Very High
Acute-phase Reaction 1 95.36 Very High Very High Very High
Coronary Artery Disease 21 94.64 High High
Rheumatoid Arthritis 448 94.24 High High
Disease 278 93.80 High High
Squamous Cell Neoplasms 3 91.52 High High
Atherosclerotic Plaque 2 90.72 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
TCZ binds to the alpha chain of both membrane-bound and soluble IL-6R, thus blocking IL-6/IL-6R signaling [2, 3].
IL-6R Binding (binds) of
1) Confidence 0.09 Published 2009 Journal Mod Rheumatol Section Body Doc Link PMC2720589 Disease Relevance 0.75 Pain Relevance 0.31
IL-6 mediates cell signaling by binding its cognate receptor (IL-6R; CD126).
IL-6R Binding (binding) of
2) Confidence 0.07 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.65 Pain Relevance 0.19
Tocilizumab is a humanized anti-human IL-6 receptor (IL-6R) monoclonal antibody that inhibits IL-6 binding to IL-6R [4].
IL-6R Binding (binding) of
3) Confidence 0.05 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638601 Disease Relevance 1.07 Pain Relevance 0.38
This binding subsequently inhibits dimerization of the IL-6/IL-6R complex with membrane-bound gp130, preventing signaling.
IL-6R Binding (dimerization) of
4) Confidence 0.05 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.36 Pain Relevance 0.13
Tocilizumab, previously known as myeloma receptor antibody (MRA), is a humanized, IgG1 IL-6 receptor monoclonal antibody that binds with high affinity to the 80 kDa component of IL-6R.
IL-6R Binding (affinity) of
5) Confidence 0.05 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.36 Pain Relevance 0.13
IL-6 mediates cell signaling by binding its cognate receptor (IL-6R; CD126).
IL-6R Binding (binding) of
6) Confidence 0.05 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.65 Pain Relevance 0.19
The binding of IL-6R complexed with IL-6 results in homodimerization of gp130 and signal transduction through Janusactivated kinase (JAK)/signal transducers and activators of transcription (STAT) pathways (Heinrich et al 2003).
IL-6R Binding (binding) of
7) Confidence 0.05 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.58 Pain Relevance 0.17
However, in order to transduce a signal, the combination of IL-6/IL-6R must also bind a ubiquitous transmembrane protein, glycoprotein (gp) 130 (CD130).
IL-6R Binding (bind) of
8) Confidence 0.05 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 0.61 Pain Relevance 0.18
IL-6 and its receptor, IL-6R, were found in various tumors, such as in the kidney, lung, ovary, H&N and cervix [9,23].
IL-6R Binding (found) of in cervix associated with cancer
9) Confidence 0.04 Published 2010 Journal Radiat Oncol Section Body Doc Link PMC2837669 Disease Relevance 1.60 Pain Relevance 0.26
Tocilizumab inhibits the induction of biological activity due to IL-6 in cells that have expressed both membrane-bound IL-6R and gp130 molecules, and also inhibits the induction of biological activity due to IL-6/IL-6R complex formation in cells that express gp130 alone.
IL-6R Binding (formation) of
10) Confidence 0.02 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727785 Disease Relevance 0.40 Pain Relevance 0.13
The blockade of the biological functions of IL-6 may theoretically be available through a blockade of the gp130 receptor by neutralizing IL-6 or by the prevention of the IL-6/IL-6R complex formation.
IL-6R Binding (formation) of
11) Confidence 0.02 Published 2010 Journal Core evidence Section Body Doc Link PMC2899792 Disease Relevance 0.37 Pain Relevance 0.23
Tocilizumab, formerly myeloma receptor antibody (MRA), is a humanized anti-IL-6R monoclonal antibody (humanized by the technique of complementary-determining region grafting from mouse anti-human IL-6R monoclonal antibody) engrafted with a human IgG1 Fc to minimize potential immunogenic responses in humans.30 It has a high affinity to IL-6R and abrogates the IL-6 signaling by preventing the formation of the IL-6/IL-6R complex.
IL-6R Binding (affinity) of
12) Confidence 0.02 Published 2010 Journal Core evidence Section Body Doc Link PMC2899792 Disease Relevance 0.54 Pain Relevance 0.17
When binding to IL-6, both soluble and membrane IL-6R connects to gp130 on the membrane whereby the intracellular signal activating the Jak-STAT pathway is mediated.8,9
IL-6R Binding (binding) of
13) Confidence 0.02 Published 2010 Journal Core evidence Section Body Doc Link PMC2899792 Disease Relevance 1.13 Pain Relevance 0.21
After forming a complex with IL-6, soluble (s) IL-6R can also combine with gp130 on the cell membrane and enables signaling (Ward et al 1994). s IL-6R is present in the blood of healthy individuals at a concentration of several tens of ng/mL, and if the cells express gp130, IL-6 signaling can take place, even in the absence of IL-6R expression on the cell membrane.
IL-6R Binding (complex) of in blood
14) Confidence 0.02 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727785 Disease Relevance 0.45 Pain Relevance 0.23
Furthermore, since it has the capacity to dissociate IL-6/IL-6R complexes that have already formed, it exhibits an extremely effective blocking action on IL-6 signal trans-duction (Figure 2).


IL-6R Binding (dissociate) of
15) Confidence 0.02 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727785 Disease Relevance 0.47 Pain Relevance 0.14
Its effects are mediated through interaction with its receptor complex, IL-6R.
IL-6R Binding (interaction) of
16) Confidence 0.01 Published 2003 Journal Cardiovasc Diabetol Section Body Doc Link PMC212422 Disease Relevance 1.27 Pain Relevance 0.56

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox